Company news
Harbin Pharmaceutical Group Co., Ltd. news in 2026
Harbin Pharmaceutical Group Co., Ltd.'s news releases, calls and decks from 2026, newest first.
(600664)"Harbin Pharmaceutical Group Co., Ltd."Report for Q3 2026
October 26, 2026
(600664)"Harbin Pharmaceutical Group Co., Ltd."Notice on Convening the 1st Extraordinary General Meeting in 2026
October 26, 2026
(600664)"Harbin Pharmaceutical Group Co., Ltd."Announcement on Resolutions of the 29th Meeting of the 10th Board of Directors
October 26, 2026
(600664)"Harbin Pharmaceutical Group Co., Ltd."Announcement on Amendment to the Articles of Association
October 26, 2026
(600664)"Harbin Pharmaceutical Group Co., Ltd."Announcement on the Affiliated Enterprise's Receipt of the Approval Notice for the Marketing Application of a Chemical API
October 12, 2026
Announcement on Imposition of Detention Measures on a Director and Senior Executive
October 11, 2026
Semi-annual Report for 2026
August 25, 2026
Announcement on Abnormal Fluctuations in Stock Trading
August 11, 2026
Announcement on the Proposed Selection in the 12th Batch of National Centralized Drug Procurement
August 3, 2026
Announcement on the Affiliated Enterprise's Receipt of the Approval Notice for the Marketing Application of a Chemical API
July 29, 2026
Announcement on Severe Abnormal Fluctuations in Stock Trading and Risk Warning
July 23, 2026
Announcement on Resolutions of the 27th Meeting of the 10th Board of Directors
July 16, 2026
Announcement on Adjustment to the Company's Products in the National Essential Medicines List
July 13, 2026
Announcement on Expected Increase in Semi-annual Performance for 2026
July 9, 2026
Announcement on Pledge of Partial Shares of Controlling Shareholder
June 24, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
June 23, 2026
Announcement on Progress in Technology Transfer (Entrustment) Contract Signed by a Wholly-owned Subsidiary and Entry of Daprodustat Tablets into Phase III Clinical Trial (Confirmatory Clinical Study)
June 10, 2026
Notice on Convening the 2025 Annual General Meeting
June 2, 2026
Announcement on Attending the Online Collective Reception Day for Investors of Listed Companies in Heilongjiang Jurisdiction in 2026 and the 2025 Annual and Q1 2026 Performance Briefing
April 29, 2026
Announcement on Change of Accounting Policies
April 22, 2026
Announcement on Abnormal Fluctuations in Stock Trading
April 15, 2026
Announcement on Resolutions of the 24th Meeting of the 10th Board of Directors
March 9, 2026
Announcement on Subsidiary's Drug Passing the Consistency Evaluation for Generic Drugs
February 10, 2026
Announcement on Affiliated Enterprise Obtaining Approval for Marketing of Chemical APIs
February 5, 2026
Announcement on Subsidiary Obtaining Drug Registration Certificate
February 2, 2026
Announcement on Estimated Daily Related Party Transactions in 2026
January 26, 2026
Announcement on the Change of Quality Control Reviewer
January 21, 2026
Announcement on the Change of Signatory Certified Public Accountant and Quality Control Reviewer
January 7, 2026